Topping tamoxifen as 1st-line Rx for postmenopausal breast Ca

Aromatase inhibitors should replace tamoxifen as the first choice for preventing recurrence of breast cancer in postmenopausal women with localized hormone receptor-positive disease, according to this large-scale study.